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Abstract
Summary The MOVEST study evaluated the efficacy and
safety of monthly oral ibandronate versus licensed monthly
IV ibandronate in Japanese osteoporotic patients. Relative
BMD gains after 12 months were 5.22 % oral and 5.34 %
IV, showing non-inferiority of oral to IV ibandronate (primary
endpoint). No new safety concerns were identified.
Introduction The randomized, phase 3, double-blind
MOVEST (Monthly Oral VErsus intravenouS ibandronaTe)
study evaluated the efficacy and safety of monthly oral
ibandronate versus the licensed monthly intravenous (IV)
ibandronate regimen in Japanese patients with osteoporosis.
Methods Ambulatory patients aged ≥55 years with primary
osteoporosis were randomized to receive oral ibandronate
100 mg/month plus monthly IV placebo, or IV ibandronate
1 mg/month plus monthly oral placebo. The primary endpoint
was non-inferiority of oral versus IV ibandronate with respect
to bone mineral density (BMD) gains at the lumbar spine after
12 months of treatment.
Results Four hundred twenty-two patients were enrolled with
372 patients in the per-protocol set (183 and 189 in the oral
and IV ibandronate groups, respectively). The relative change
from baseline in lumbar spine BMD values for the oral and IV
ibandronate groups, respectively, was 5.22 % (95 % confi-
dence interval [CI] 4.65, 5.80) and 5.34 % (95 % CI 4.78,
5.90). The least squares mean difference between the two
groups was −0.23 % (95 % CI −0.97, 0.51), showing non-
inferiority of oral ibandronate to IV ibandronate (non-inferior-
ity limit=−1.60). Changes in BMD values at other sites, and
bone turnover marker levels in the oral ibandronate group,
were comparable with those of the IV group. The safety pro-
file was similar to that previously demonstrated; no new safety
concerns were identified.
Conclusions This study demonstrated the non-inferiority of
oral ibandronate 100 mg/month to IV ibandronate 1 mg/
month (licensed dose in Japan) in increasing lumbar spine
BMD in Japanese patients with primary osteoporosis.
Keywords Ibandronate . MOVESTstudy . Oral dosing .
Osteoporosis
Introduction
The efficacy of ibandronate as a daily treatment regimen was
initially demonstrated in the BONE study (oral iBandronate
Osteoporosis vertebral fracture trial in North America and
Europe) [1]. Monthly and quarterly dosing regimens of
bisphosphonates were subsequently developed with the aim
of maintaining adherence and improving outcomes. Based on
the bridging strategy, and evidence of an association between
bone mineral density (BMD) increases and anti-fracture
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efficacy [2], the MOBILE (Monthly Oral iBandronate In La-
diEs) and DIVA (Dosing IntraVenous Administration) regis-
tration trials were conducted and showed superior BMD in-
creases with monthly oral and quarterly intravenous (IV)
ibandronate, respectively, versus the daily oral regimen
[3–5]. Increases in BMD at all sites were maintained in
long-term extensions of these two trials [6, 7].
Meta-analyses of these registration trials confirmed the sig-
nificant efficacy of monthly oral and quarterly IV regimens of
ibandronate in risk reduction of not only vertebral fractures but
also non-vertebral and clinical fractures [8, 9]. In addition, a
post hoc analysis of individual patient data from the MOBILE
and DIVA studies, plus the long-term extensions, revealed a
significantly longer time to fracture with intermittent regimens
of ibandronate than with placebo over 5 years [10]. These anal-
yses indicated that ibandronate regimens with an annual cumu-
lative exposure (ACE) ≥10.8 mg (i.e., monthly oral 150 mg,
quarterly IV 3 mg/3 months) significantly reduced the risk of
non-vertebral fractures, including hip fractures, compared with
ibandronate regimens with low ACE or placebo.
In Japan, the development of IV regimens of ibandronate
was prioritized and the ACE concept was considered. The
phase 3 MOVER (MOnthly intraVenous ibandronatE versus
daily oral Risedronate) study, conducted for registration pur-
poses in Japan, was designed to demonstrate the non-
inferiority of IV ibandronate 1 mg/month (ACE of 12.0 mg)
to oral risedronate in vertebral fracture risk reduction. Results
of the study showed that IV ibandronate 1 mg/month consis-
tently reduced the incidence of not only vertebral fractures but
also non-vertebral fractures, compared with risedronate [11].
Conversely, the optimal dose of monthly oral ibandronate in
Japanese osteoporotic patients has not yet been determined.
However, the oral 150 mg/month dose is widely used inWest-
ern countries with Caucasian (or non-Asian) patients with
osteoporosis. The licensed oral doses of alendronate and
risedronate for the treatment of osteoporosis in Japan are half
those given in Western countries [12–17], whereas the results
of the phase 2 dose-finding study with monthly oral
ibandronate showed that 100 mg was considered to be the
optimal dose for Japanese patients [18].
The purpose of the current registration study was to exam-
ine the efficacy and safety of monthly oral ibandronate
100 mg for Japanese patients with osteoporosis and to dem-
onstrate its non-inferiority versus monthly IV ibandronate
1 mg in terms of BMD increases after 12 months of treatment.
Materials and methods
Study design
The MOVEST (Monthly Oral VErsus intravenouS
ibandronaTe) study was a prospective, multicenter,
randomized, double-blinded, double-dummy comparative
study that compared oral ibandronate 100 mg/month with IV
ibandronate 1 mg/month in Japanese women and men with
osteoporosis (Clinical trial number JapicCTI-121982). The
primary endpoint was the non-inferiority of oral ibandronate
versus IVibandronate with respect to lumbar spine BMD (L2–
L4) gains after 12 months of treatment.
Patients
Japanese women and men aged ≥55 years with primary oste-
oporosis according to the Diagnosis Criteria of Primary Oste-
oporosis in Japan [19] were eligible. Patients were required to
have BMD of the lumbar spine (L2–L4) <70 % of the young
adult mean (T score less than −2.6 standard deviations [SD])
or BMD of the lumbar spine (L2–L4) <80 % of the YAM (T
score less than −1.7 SD) with fragile bone fracture (non-
traumatic osteoporotic fracture that occurred by slight
external force combined with low BMD).
Exclusion criteria included vertebral deformations likely to
affect lumbar spine (L2–L4) BMD measurements by dual-
energy x-ray absorptiometry (DXA) scan in central review;
previous radiotherapy of the thoracic spine/lumbar spine/pel-
vis; secondary osteoporosis or a disease causing decrease in
bone volume; a disorder delaying the passage of food through
the esophagus; received/planned invasive dental procedures;
bisphosphonate use within 1 year of the start of the study, anti-
receptor activator of nuclear factor-κB ligand (RANKL) anti-
body (AMG162) use within 2 years of the start of the study, or
prior treatment with ibandronate, zoledronate, cathepsin K
inhibitor, anti-sclerostin antibody, parathyroid hormone, or
strontium; receipt of drugs likely to affect bone metabolism
within 8 weeks of the start of the study; severe cardiac, renal,
or hepatic disease; calcium outside the criteria value (<8.4 or
>10.4 mg/dL); hypersensitivity to bisphosphonate, calcium,
or vitamin D; and active malignant tumor or prior therapy
for malignant tumor within 3 years.
Treatment
Patients were randomly assigned to receive 100 mg/month
oral ibandronate (F. Hoffmann-La Roche, Ltd.) plus IV place-
bo, or 1 mg/month IV ibandronate (F. Hoffmann-La Roche,
Ltd.) plus oral placebo for 12 months by the double dummy
method. Patients were instructed to take ibandronate or place-
bo tablets 60 min before their first food or drink of the day,
swallowed whole with a full glass of water while sitting or
standing in an upright position. All patients received supple-
mentary calcium 610 mg and vitamin D 400 IU/day from the
registration date until the end of the study. Study drug
administration was recorded by the investigator at the
time of dosing.
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Randomization and blinding
Randomization was performed centrally through dynamic al-
location (minimization method) based on the patient’s L2–L4
BMD value at screening (T-score <−3.0 vs. ≥−3.0). Patients,
investigators, steering committee members, the sponsor, and
the faculty who adjudicated the study endpoints remained un-
aware of treatment-group assignments throughout the trial.
Study endpoints
The primary endpoint was the percentage change from base-
line in lumbar spine (L2–L4) BMD at 12 months. Secondary
endpoints were the percentage change from baseline in total
hip, femoral neck, and trochanter BMD; change from baseline
in bone turnover markers (BTMs) of urinary C-telopeptide of
type 1 collagen corrected by creatinine (uCTX), serum
tartrate-resistant acid phosphatase 5b (TRAP 5b), urinary N-
telopeptide of type 1 collagen corrected by creatinine (uNTX),
serum procollagen type 1N-terminal propeptide (P1NP), and
serum bone-specific alkaline phosphatase (BALP); incidences
of non-traumatic new vertebral or non-vertebral fractures; and
safety.
Schedule of assessments
BMD measurements at the lumbar spine (L2–L4), total hip,
femoral neck, and trochanter were performed centrally
(BioClinica, Newark, CA, USA) at screening, baseline, 4, 6,
and 12 months using DXA of Hologic bone densitometers.
Measurements of a quality control phantom were collected
and analyzed by BioClinica to monitor the stability of each
DXA scanner. Each study site received the cross-calibration
phantom and cross-calibration scans were sent to BioClinica
for processing and statistical analysis. BTMs were measured
centrally (LSI Medience Corporation, Tokyo, Japan) at base-
line, 1, 3, 6, and 12 months. All samples were obtained under
fasting conditions prior to study drug administration.
Radiographs of the thoracic and lumbar spine were taken at
screening, baseline, and at 12 months after treatment for the
assessment of fracture incidence. To identify morphometric
vertebral fractures, the vertebral bodies of the lateral projec-
tion from Th4 to L4 were assessed using semiquantitative
(SQ) methodology by a central committee who were blinded
to treatment. Avertebral fracture was defined as an increase of
≥1 SQ grading scale in a vertebra from baseline. Radiographs
were assessed by investigators to identify non-vertebral frac-
tures in patients with clinical symptoms.
Adverse events (AEs) were collected throughout the study
period and for up to 28 days after the end of treatment. AEs of
interest such as renal, cardiac, and gastrointestinal (GI) disor-
ders, esophageal irritation, acute phase reactions (APRs; oc-
curring within 3 days of dosing and lasting for no longer than
7 days), hypocalcemia, osteonecrosis of the jaw, and atypical
fracture of the femur were specified in advance.
Statistical analyses
The primary analysis was performed on the per-protocol set
(PPS). Analyses of BMD and BTMs were analyzed on the
relative change from baseline. Missing data were imputed by
the last observation carried forward method. An analysis of
covariance was used for the comparison of the relative change
in BMD gains at the lumbar spine at 12 months between the
two treatment groups with covariates as the BMD and P1NP
values at baseline, interaction of BMDvalues at baseline, prior
therapy with bisphosphonates and other osteoporotic agents
except bisphosphonates. The covariates, except BMD values
at baseline, were added based on a blind review of data. The
non-inferiority limit for oral ibandronate to IV ibandronate
was set at −1.6. If the lower limit of the 95 % confidence
interval (CI) of the least squares mean difference was above
the non-inferiority limit, the non-inferiority of oral
ibandronate to IV ibandronate would be concluded.
Based on analyses in the MOVER study [11], the relative



























Fig. 1 Patient flow through the
study. IV intravenous
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ibandronate after 12 months of treatment was estimated to be
comparable and its SD was estimated to be 4.5 %. The non-
inferiority margin was set within 1.6 %, with a one-sided
significance level of 0.05 and a detection power of 90%.With
an expected drop-out rate of 15 %, 168 patients were required
in each treatment group for analysis, and 198 patients were
targeted for registration purposes.
Results
Patient disposition and baseline characteristics
A total of 422 patients were enrolled. Fourteen patients did not
receive any study drug, leaving 205 and 203 patients (198 and
199 women) in the safety population who were randomized to
receive oral ibandronate 100 mg/month and IV ibandronate
1 mg/month, respectively (Fig. 1). Overall, 177 and 184 pa-
tients in the oral and IV ibandronate groups, respectively,
completed the study. The PPS for the primary endpoint anal-
ysis comprised 183 and 189 patients in the oral 100 mg/month
and IV 1 mg/month groups, respectively. Baseline patients’
characteristics between the two treatment groups were well
balanced (Table 1).
Bone mineral density
Similar BMD gains were observed with the two treatment
regimens throughout the study. The mean relative change
from baseline in lumbar spine BMD at 12 months was
5.22 % (95 % CI 4.65, 5.80) and 5.34 % (95 % CI 4.78,
5.90) with oral and IV ibandronate, respectively (Fig. 2a).
The least squares mean difference between the two groups
was −0.23 % (95 % CI −0.97, 0.51), showing the non-
inferiority of oral ibandronate 100 mg/month to IV
ibandronate 1 mg/month (non-inferiority limit=−1.60). Sensi-
tivity analysis showed that the result of the primary analysis
was robust with or without the added covariates (data not
shown). Mean relative changes from baseline to 12 months
in total hip BMD were 2.41 % (95 % CI 1.95, 2.87) with oral
ibandronate and 2.76 % (95 % CI 2.33, 3.19) with IV
ibandronate (Fig. 2b), and in femoral neck BMD were
2.58 % (95 % CI 1.87, 3.29) and 2.64 % (95 % CI 2.06,
3.23), respectively (Fig. 2c). BMD responder rates at the
Table 1 Baseline patient
characteristics Characteristic Ibandronate
Oral 100 mg/month (n=183) IV 1 mg/month (n=189)
Women, n (%) 177 (96.7) 186 (98.4)
Age, years (SD) 68.8 (6.94) 69.3 (6.02)
55–74 years, n (%) 138 (75.4) 156 (82.5)
≥75 years, n (%) 45 (24.6) 33 (17.5)
Weight, kg (SD) 49.5 (7.2) 49.2 (6.7)
Height, cm (SD) 152.2 (6.5) 151.6 (6.1)
BMD T-score (SD)
Lumbar spine (L2–L4) −3.09 (0.58) −3.14 (0.60)
Total hip −2.41 (0.84) −2.47 (0.79)
Femoral neck −2.98 (0.82) −2.99 (0.78)
Prevalent vertebral fractures, n (%)
0 124 (67.8) 130 (68.8)
1 34 (18.6) 34 (18.0)
≥2 25 (13.7) 25 (13.2)
uCTX, μg/mmol CR (SD) 247.9 (138.8) 249.4 (166.4)
TRAP 5b, mU/dL (SD) 387.4 (131.6) 389.2 (152.8)
P1NP, μg/L (SD) 50.6 (21.36) 49.0 (22.30)
BALP, μg/L (SD) 17.1 (6.78) 16.5 (6.91)
25-OH(D), ng/mL (SD) 25.3 (6.26) 25.3 (5.84)
Values are the mean, except where indicated
BALP bone-specific alkaline phosphatase, BMD bone mineral density, CR creatinine, IV intravenous, P1NP
procollagen type 1N-terminal propeptide, SD standard deviation, TRAP 5b tartrate-resistant acid phosphatase 5b,
uCTX creatinine-corrected urinary collagen type 1 cross-linked C-telopeptide, 25-OH(D) 25-hydroxyvitamin D
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lumbar spine, total hip, and femoral neck were consistent be-
tween the two groups after 12 months of treatment (Table 2).
Bone turnover markers
The mean relative change from baseline in uCTX, serum
TRAP 5b, and uNTX levels as bone resorption markers, and
in serum P1NP and serum BALP, was similar throughout
12 months of oral and IV ibandronate treatment (Fig. 3, uNTX
data not shown). The decrease from baseline in uCTX levels
at 12 months was 62.80 % (95 % CI 56.62, 68.97) with oral
ibandronate and 59.51 % (95 % CI 53.70, 65.33) with IV
ibandronate (Fig. 3a). The decrease in TRAP 5b levels was
46.42 % (95 % CI 43.99, 48.85) and 44.65 % (95 % CI 41.84,
47.45), respectively (Fig. 3b). Decreases in serum P1NP were
68.98 % (95 % CI 66.95, 71.02) and 66.66 % (95 % CI
63.45, 69.87), respectively, with oral and IV ibandronate
(Fig. 3c), and in serum BALP were 47.28 % (95 % CI
45.03, 49.53) and 43.35 % (95 % CI 40.30, 46.40),
respectively (Fig. 3d).
Fractures
No differences in fracture incidence were observed between
the two treatment groups. The incidence of vertebral fracture
over 12 months was 1.1 % (2/183) with oral ibandronate and
0.5 % (1/189) with IV ibandronate. The cumulative incidences
of non-vertebral fractures over 12 months were 1.1 % (2/183)
and 2.6 % (5/189), respectively.
Adverse events
No apparent differences were observed between the two treat-
ment groups with respect to the incidence of all AEs, all drug-
related AEs, or AEs leading to withdrawal (Table 3). The
incidence of GI-related AEs was 12.2 and 9.9 % in the oral
and IV ibandronate groups, respectively. The incidence of
APRs was also similar between the two groups: 11.2 and
11.8 % in the oral and IV ibandronate groups, respectively.
However, APR AEs in the oral ibandronate group were mild
in intensity, except for three moderate cases (one bone pain
and two APR as preferred term), and all APR AEs in the IV
ibandronate group were mild. In both treatment groups, APR
AEs were transient and decreased with each subsequent dose

























































































Fig. 2 Mean relative change from baseline to 12 months (with 95 % CI)
in BMD at the a lumbar spine (L2–L4), b total hip, and c femoral neck.
BMD bone mineral density, CI confidence interval, IV intravenous
Table 2 Responder rates (with 95 % CI) after 12 months of treatment
Responder ratea (%) Ibandronate
Oral 100 mg/month IV 1 mg/month
Patients with >0 % increase in BMD
L2–L4 91.8 (86.8, 95.3) 92.1 (87.2, 95.5)
Total hip 86.2 (80.3, 90.9) 91.5 (86.6, 95.1)
Femoral neck 71.3 (64.1, 77.7) 74.1 (67.2, 80.2)
Patients with ≥3 % increase in BMD
L2–L4 71.6 (64.5, 78.0) 75.7 (68.9, 81.6)
Total hip 39.2 (32.1, 46.7) 43.4 (36.2, 50.8)
Femoral neck 43.1 (35.8, 50.6) 41.8 (34.7, 49.2)
BMD bone mineral density, CI confidence interval, IV intravenous
a Defined as the proportion of patients with mean lumbar spine (L2–L4),
total hip, or femoral neck BMD above baseline
Osteoporos Int (2015) 26:2685–2693 2689
interest, the incidence of esophageal irritation-related AEswas
1.0 and 2.5 % with oral and IV ibandronate, respectively.
There were no renal function-related AEs, hypocalcemia,
osteonecrosis of the jaw, or atypical fracture of the femur
(Table 3).
Discussion
We compared the efficacy and safety of oral 100 mg/month
and IV 1 mg/month ibandronate in terms of changes in BMD
and BTMs in Japanese patients with primary osteoporosis for
registration purposes. Oral ibandronate was non-inferior to IV
ibandronate with respect to lumbar spine BMD gains after
12 months of treatment. BMD gains at femur sites and BTM
suppression with oral ibandronate were consistent with those
of IV ibandronate. The safety profile of oral ibandronate was
comparable not only with that of IV ibandronate but also with
that of previously examined intermittent ibandronate regimens
[1, 3, 6]. The oral ibandronate regimen was well tolerated.
BMD gains have been recognized as a surrogate marker for
future fracture risk. The relationship between increases in
BMD and fracture risk reduction by treatment with
ibandronate has been reported previously [20, 21]. Patients
receiving ibandronate at high ACE (10.8–12.0 mg) showed
higher BMD increases and stronger anti-fracture efficacy than
those treated at low ACE (5.5 mg) [9]. In the MOVER study,
IV ibandronate 1 mg/month (ACE of 12.0 mg) demonstrated
non-inferiority to risedronate in terms of vertebral fracture risk
reduction [11]. The fact that the oral ibandronate 100 mg/
month regimen was bridged to the IV 1 mg/month regimen
in this study suggests that monthly oral ibandronate 100 mg
would be efficacious in fracture risk reduction.
Nakai et al. recently reported that the area under the
ibandronate serum-concentration time curve (AUC) and the
relative change in uCTX levels with oral ibandronate 100 mg/
month were comparable with those of IV ibandronate 1 mg/
month in Japanese postmenopausal women [22]. The optimal
monthly dose of ibandronate for Japanese patients was con-
firmed as 100 mg, based on the results of the phase 2 dose-
finding study [18] and the current pivotal bridging clinical
trial. The optimal monthly dose for Caucasian patients in
Western countries is 150 mg, which is higher than that for
Japanese patients. The bioavailability of oral ibandronate is
reported to be 0.63 % in Western populations [23] and
0.91 % in Japanese populations [22]. This 1.44-times higher
bioavailability in Japanese patients could lead to a 1.5-times










































































































Fig. 3 Mean relative change from baseline to 12 months (with 95 % CI)
in a uCTX, b serum TRAP 5b, c serum P1NP, and d serum BALP. BALP
bone-specific alkaline phosphatase, CI confidence interval, IV
intravenous, P1NP procollagen type 1N-terminal propeptide, TRAP 5b
tartrate-resistant acid phosphatase 5b, uCTX creatinine-corrected urinary
collagen type 1 cross-linked C-telopeptide
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bioavailability of bisphosphonates, including risedronate, in
Japanese patients has been reported to be slightly higher than
inWestern populations [24–26]. The reason for this difference
in bioavailability is still unknown [22]. Overall, exposure to
ibandronate is similar in Japanese and Western populations
because of dose optimization in the different settings. This
suggests that oral ibandronate, when dosed optimally, offers
similar efficacy and safety benefits to Japanese and Western
patients.
The safety profile of ibandronate in this current study
was similar to previous studies in Western patients with
no apparent increase in the nature or severity of AEs.
APR is commonly experienced following the first ad-
ministration of nitrogen-containing bisphosphonates.
The incidence of APR AEs was similar with monthly
oral and IV ibandronate, administered at comparable
ACE, and they were reported at a similar frequency to
previous studies [3, 4, 11]. The incidence of GI-related
AEs was also similar between the treatment groups.
Thus, oral ibandronate 100 mg/month appears to be
well tolerated by Japanese osteoporotic patients with a
similar safety profile to the established monthly oral
regimen in Western populations.
There are some limitations to this study. Firstly, regarding
concerns about GI-related AEs with oral bisphosphonate treat-
ment, the incidence of these AEs in the current study may not
reflect the effects seen in daily practice due to the double
dummy design used. In addition, we assessed fracture inci-
dence over 12 months of treatment, but there are as yet limited
data on the fracture incidence with 100 mg/month ibandronate
in Japanese patients over longer treatment periods. Further
clinical evidence must be accumulated on long-term treatment
duration in this patient population.
Better adherence to treatment can lead to improved out-
comes in patients with osteoporosis, both in terms of BMD
gains and in f rac tu re r i sk reduc t ion . Al though
Table 3 Summary of adverse
events AE, n (%) Ibandronate
Oral 100 mg/month (n=205) IV 1 mg/month (n=203)
Any AE 175 (85.4) 177 (87.2)
Drug-related AE 47 (22.9) 38 (18.7)
Severe intensity AE 2 (1.0) 0
Serious AE 9 (4.4) 6 (3.0)
AEs leading to death 0 0
AEs leading to treatment withdrawal 4 (2.0) 4 (2.0)
AEs occurring in ≥5 % of patients in either group
Nasopharyngitis 48 (23.4) 62 (30.5)
Back pain 22 (10.7) 24 (11.8)
Contusion 17 (8.3) 13 (6.4)
Osteoarthritis 12 (5.9) 4 (2.0)
Muscle pain 4 (2.0) 11 (5.4)
AEs of special interest
GI related 25 (12.2) 20 (9.9)
Esophageal irritation 2 (1.0) 5 (2.5)
APRa related 23 (11.2) 24 (11.8)
Back pain 7 (3.4) 6 (3.0)
APR 5 (2.4) 4 (2.0)
Malaise 5 (2.4) 2 (1.0)
Arthralgia 2 (1.0) 4 (2.0)
Myalgia 0 4 (2.0)
Renal function related 0 0
Hypocalcemia 0 0
Osteonecrosis of the jawb 0 0
Atypical fracture of the femurb 0 0
AE adverse event, APR acute phase reaction, GI gastrointestinal, IV intravenous
a Occurring within 3 days of dosing and lasting for no longer than 7 days; APR AEs occurring at an incidence of
≥2 % of patients in either treatment group are listed
bAs per the American Society of Bone and Mineral Research case definition
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bisphosphonates have been used as first-line therapy for many
years, their complex dosing instructions have resulted in
adherence issues with long-term treatment. Adherence is
higher with weekly rather than daily bisphosphonates
[27] and with monthly rather than weekly treatment
[28, 29]. A preference for monthly oral bisphosphonates
has also been reported [30, 31]. These findings suggest
that the availability of a monthly oral ibandronate dos-
ing regimen would create an opportunity to improve
adherence in Japanese patients with osteoporosis.
In conclusion, oral ibandronate 100 mg/month dem-
onstrated non-inferiority to IV ibandronate 1 mg/month
(licensed dose in Japan) in lumbar spine BMD gains in
Japanese patients with primary osteoporosis. The safety
profile of oral and IV ibandronate was similar, and
monthly oral ibandronate was as well tolerated in Japa-
nese patients as in Western patients. These data suggest
that these two different monthly ibandronate regimens
are effective alternatives for the treatment of osteoporo-
sis in Japanese patients.
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